1             Key Insights

2             Respiratory Syncytial Virus Market Overview at a Glance

2.1         Market Share (%) Distribution of Respiratory Syncytial Virus in 2017

2.2         Market Share (%) Distribution of Respiratory Syncytial Virus in 2026

3             Executive Summary of Respiratory Syncytial Virus 

4             Respiratory Syncytial Virus: Disease Background and Overview

4.1         Introduction

4.2         Causes

4.3         Pathophysiology

4.4         Symptoms

4.5         Risk Factors

4.6         Diagnosis

5             Diagnostic Algorithm for Respiratory Syncytial Virus 

6             Clinical Algorithm for Respiratory Syncytial Virus 

7             Epidemiology and Patient Population

7.1         Key Findings

7.2         Total Incidence Population of Respiratory Syncytial Virus 

7.3         Total Diagnosed Incidence Population of Respiratory Syncytial Virus 

7.4         Case-specific Diagnosed Prevalent Population of Respiratory Syncytial Virus 

7.5         Age-specific Diagnosed Prevalent Population of Respiratory Syncytial Virus 

8             Region Wise-Epidemiology of Respiratory Syncytial Virus 

8.1         Assumptions and Rationale

8.2         North America

8.2.1      Assumptions and Rationale

8.2.2      Total Incidence Population of Respiratory Syncytial Virus 

8.2.3      Total Diagnosed Incidence Population of Respiratory Syncytial Virus 

8.2.4      Case-specific Diagnosed Prevalent Population of Respiratory Syncytial Virus 

8.2.5      Age-specific Diagnosed Prevalent Population of Respiratory Syncytial Virus 

8.3         Europe

8.3.1      Assumptions and Rationale

8.3.2      Total Incidence Population of Respiratory Syncytial Virus 

8.3.3      Total Diagnosed Incidence Population of Respiratory Syncytial Virus 

8.3.4      Case-specific Diagnosed Prevalent Population of Respiratory Syncytial Virus 

8.3.5      Age-specific Diagnosed Prevalent Population of Respiratory Syncytial Virus 

8.4         Asia-Pacific

8.4.1      Assumptions and Rationale

8.4.2      Total Incidence Population of Respiratory Syncytial Virus 

8.4.3      Total Diagnosed Incidence Population of Respiratory Syncytial Virus 

8.4.4      Case-specific Diagnosed Prevalent Population of Respiratory Syncytial Virus 

8.4.5      Age-specific Diagnosed Prevalent Population of Respiratory Syncytial Virus 

8.5         Middle-East and Africa

8.5.1      Assumptions and Rationale

8.5.2      Total Incidence Population of Respiratory Syncytial Virus 

8.5.3      Total Diagnosed Incidence Population of Respiratory Syncytial Virus 

8.5.4      Case-specific Diagnosed Prevalent Population of Respiratory Syncytial Virus 

8.5.5      Age-specific Diagnosed Prevalent Population of Respiratory Syncytial Virus 

8.6         South America

8.6.1      Assumptions and Rationale

8.6.2      Total Incidence Population of Respiratory Syncytial Virus 

8.6.3      Total Diagnosed Incidence Population of Respiratory Syncytial Virus 

8.6.4      Case-specific Diagnosed Prevalent Population of Respiratory Syncytial Virus 

8.6.5      Age-specific Diagnosed Prevalent Population of Respiratory Syncytial Virus 

9             Treatment

10           Treatment Algorithm for Respiratory Syncytial Virus 

11           Marketed drugs

11.1       VIRAZOLE: Valeant

11.1.1    Drug Description

11.1.2    Regulatory Milestones

11.1.3    Other Development Activities

11.1.4    Safety and Efficacy

11.1.5    Product profile

11.2       Synagis® (palivizumab): MedImmune: Abbott Laboratories, Inc.

11.2.1    Drug Description

11.2.2    Regulatory Milestones

11.2.3    Other Development Activities

11.2.4    Safety and Efficacy

11.2.5    Product profile

Continued in the report...

12           Emerging Drugs

12.1       RRV521 (Sisunatovir): ReViral

12.1.1    Product Description

12.1.2    Other Development Activities

12.1.3    Clinical Development

12.1.4    Clinical TriRSV Information

12.1.5    Safety and Efficacy

12.1.6    Product Profile

12.2       EDP-938: Enanta Pharmaceuticals

12.2.1    Product Description

12.2.2    Other Development Activities

12.2.3    Clinical Development

12.2.4    Clinical TriRSV Information

12.2.5    Safety and Efficacy

12.2.6    Product Profile

12.3       Nirsevimab: AstraZeneca

12.3.1    Product Description

12.3.2    Other Development Activities

12.3.3    Clinical Development

12.3.4    Clinical TriRSV Information

12.3.5    Safety and Efficacy

12.3.6    Product Profile

12.4.6    Product Profile

Continued in the report...

13           Respiratory Syncytial Virus: Regional Market Analysis

13.1       Key Findings

13.2       Market Size of Respiratory Syncytial Virus 

14           The North America Market Outlook

14.1       North America Market Size

14.1.1    Total Market size of Respiratory Syncytial Virus 

14.1.2    Market Size by Treatment Type

14.1.3    Market Size by End users

15           Europe: Market Outlook

15.1       Europe Market Size

15.1.1    Total Market size of Respiratory Syncytial Virus 

15.1.2    Market Size by Treatment Type

15.1.3    Market Size by End users

16           Asia-Pacific Market Outlook

16.1       Asia-Pacific Market Size

16.1.1    Total Market size of Respiratory Syncytial Virus 

16.1.2    Market Size by Treatment Type

16.1.3    Market Size by End users

17           Middle-East and Africa Market Outlook

17.1       Middle-East and Africa Market Size

17.1.1    Total Market size of Respiratory Syncytial Virus 

17.1.2    Market Size by Treatment Type

17.1.3    Market Size by End users

18           South America Market Outlook

18.1       South America Market Size

18.1.1    Total Market size of Respiratory Syncytial Virus 

18.1.2    Market Size by Treatment Type

18.1.3    Market Size by End users

19           Market Drivers

20           Market Barriers

21           SWOT Analysis of Respiratory Syncytial Virus 

22           Appendix

22.1       Report Methodology

23           About Report Ocean